Fernández MFS, Toirán GR, Varela ÁA, Segura RO

Language: Spanish
References: 21
Page: 42-49
PDF size: 428.26 Kb.

ABSTRACT

Background: prostate cancer presents the second most frequent malignant tumor in men in Cuba, only preceded by lung cancer. This type of cancer is also the second in causing more deaths in this group; besides, it affects the quality of life. Since there is a proportional correlation between the values of the prostate-specific antigen (PSA) and the anatomical-clinical results, some diagnosis will be made in early stages; as a result, treatments will be early applied with a better prognosis.
Objective: to describe the correlation between the values of PSA and the anatomical-clinical results in patients with prostate cancer.
Methods: an observational, descriptive, prospective, cross-sectional study was conducted with the objective of correlating the values of PSA and the anatomical-clinical results in patients diagnosed with prostate cancer in the Maria Curie Provincial Oncological Hospital of Camagüey, from January, 2010 to January, 2014.
Results: the greatest number of patients with prostate cancer was found between 65-84 years old. The PSA level that had the greatest frequency of positive cases was of 10-25 ng/ml, followed by the level of more than 25 ng/ml. Normal results of PSA do not exclude the existence of prostate cancer and the values of more than 25 ng/ml bore a close relation with the results of the biopsy and rectal touch.
Conclusions: the correct performance in the PSA test and in the rectal touch lead to the early diagnosis of prostate cancer with a proper anatomical-clinical correlation.

REFERENCES

1. Bastian PJ, Nuhn P, Stadler TC, Roosen A, Stief CG. Prostatic inflammation and pros-tate cancer. Urologe A. 2010 May;49(5):636-8.

2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality Re-sults from a Randomized Prostate-Cancer Screening Trial. N Engl J Med. 2009 Mar 26;360(13):1320-8.

3. Ministerio de Salud Pública, Dirección Na-cional de Registros Médicos y Estadísticos de Salud. Anuario Estadístico de Salud 2012. La Habana: OPS/UNFPA/UNICEF; 2013. Mortalidad por algunos tumores ma-lignos. 2000,2011-2012 (próstata); p. 58.

4. Ministerio de Salud Pública, Dirección Na-cional de Registros Médicos y Estadísticos de Salud. Anuario Estadístico de Salud 2012. La Habana: OPS/UNFPA/UNICEF; 2013. Incidencia de cáncer según sexo y principales localizaciones. 2009 (próstata); p. 93.

5. Ministerio de Salud Pública, Dirección Na-cional de Registros Médicos y Estadísticos de Salud. Anuario Estadístico de Salud 2012. La Habana: OPS/UNFPA/UNICEF; 2013. Incidencia de cáncer en población masculina de 60 años y más según princi-pales localizaciones y grupo de edad. 2009 (próstata); p. 101.

6. Harnden P, Shelley MD, Naylor B, Coles B, Mason MD. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review. Eur Urol. 2008;54(4):728-39.

7. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M. El Manual Merck de diagnóstico y tratamiento. T VIII. 11ed. España: Editorial Elsevier; 2007.

8. Estapé Rodríguez J, Gran de Castro JJ, Vi-ñola Segarra N, Danieli Mestre M. Diagnós-tico de extensión y estratificación terapéu-ticos diversos tumores sólidos. En: Farre-ras R, editor. Medicina Interna. Oncológica Médica: Cáncer de próstata. España: Else-vier; 2010. p. 1166.

9. Dobosy JR, Roberts JL, Fu VX, Jarrad DF. The expanding in the Development, diag-nosis and treatmen of prostate cancer and benign prostatic hiperplasia. J Urol. 2007 Mar;177(3):822-31.

10. Centro de inmunoensayo. UMELISA PSA. Para la cuantificación del Antígeno Especí-fico de Prostata en suero Humano. La Ha-bana: Centro de inmunoensayo; 2003.

11. Noronha Marcelo R, Quintal Maisa MQ, Magna Luis A, Reis Leonardo O, Billis At-hanase, Meirelles Luciana R. Controversial predictors of biochemical recurrence after radical prostatectomy: a study from a La-tin American (Brazilian) Institution. Int Braz J Urol. 2013 Dec;39(6):34-11.

12. Johansson JE, Adami HO, Andersson O, Bergstrom R, Holmberg L, Krusemo V. High 10- years survival rate in patients with early untreated prostatic cancer. JA-MA. 1992 Apr 22-29;267(16):2191-6.

13. Montano Luna JA, Prieto Díaz V. Enfoque preventivo y factores de riesgo. En: Álva-rez Sintes R, editor. Medicina General In-tegral. Ciudad de La Habana: ECIMED; 2008. p. 735-61.

14. Mc. Green L, Smith D, Bullock A. Racial difference in operating characteristic of prostate cancer screen test. J Urol. 1997 Nov;158(5):1865-6.

15. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging and update form the National Cancer Data Base. Cancer. 2003 Sep 15;98(6):1169-78.

16. Parker CC, Norman AR, Huddart RA, Huddart A, Dearnaley DP. Pre-treatment nomogram for biochemical failure after neoadjuvant androgen deprivation and radical radiotherapy for clinically local-ized prostate cancer. Br J Cancer. 2002 Mar 4;86(5):686-91.

17. Robers RO, Bergstralh EK, Besse JA, Lieber MM, Jacobsen SJ. Trends and risk factors for prostate biopsy complications in the pre- PSA and PSA eras.1980-1997. Urology. 2002 Jan;59(1):79-84.

18. Kupka da Silva R, Dall'oglio MF, Crip-pa Sant'ana A, Pontes Júnior J, Srougi M. Can Single Positive Core Prostate Cancer at biopsy be Considered a Low-Risk Disease after Radical Prostatecto-my? Int Braz J Urol. 2013 Dec;39(6):12-4.

19. De Nunzio C, Lombardo R, Albisinni S, Gacci M, Tubaro A. Serum levels of Sex Hormone Binding Globulin (SHBG) are not predictive of prostate cancer diag-nosis and aggressiveness: results from an italian biopsy cohort. Int Braz J Urol. 2013 Nov-Dec;39(6):25-9.

20. Harty Niall J, Kozinn Spencer I, Canes D, Sorcini A, Moinzadeh A. Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy. Int Braz J Urol. 2013 Oct;39(5):34-41.

21. Sadi MV. Prostate cancer screening with PSA: "Aequanimitas". Int Braz J Urol. 2013 Aug;39(4):34-9.